 NGM Biopharmaceuticals Inc NASDAQ: NGM announced preliminary findings from its ongoing Phase 1a1b dose-escalation study of NGM120 in solid tumors. Related Link: Raymond James Upgraded This Biopharma Stock And Sees 44 Upside. 